110 related articles for article (PubMed ID: 12359140)
21. Biomarker responses correlate with antibody status in mucopolysaccharidosis type I patients on long-term enzyme replacement therapy.
Langereis EJ; van Vlies N; Church HJ; Geskus RB; Hollak CE; Jones SA; Kulik W; van Lenthe H; Mercer J; Schreider L; Tylee KL; Wagemans T; Wijburg FA; Bigger BW
Mol Genet Metab; 2015 Feb; 114(2):129-37. PubMed ID: 25467058
[TBL] [Abstract][Full Text] [Related]
22. Enzyme replacement therapy started at birth improves outcome in difficult-to-treat organs in mucopolysaccharidosis I mice.
Baldo G; Mayer FQ; Martinelli BZ; de Carvalho TG; Meyer FS; de Oliveira PG; Meurer L; Tavares A; Matte U; Giugliani R
Mol Genet Metab; 2013 May; 109(1):33-40. PubMed ID: 23562162
[TBL] [Abstract][Full Text] [Related]
23. Plasma Pharmacokinetics of Valanafusp Alpha, a Human Insulin Receptor Antibody-Iduronidase Fusion Protein, in Patients with Mucopolysaccharidosis Type I.
Pardridge WM; Boado RJ; Giugliani R; Schmidt M
BioDrugs; 2018 Apr; 32(2):169-176. PubMed ID: 29442294
[TBL] [Abstract][Full Text] [Related]
24. Enzyme replacement therapy in mucopolysaccharidosis type I.
Miebach E
Acta Paediatr Suppl; 2005 Mar; 94(447):58-60; discussion 57. PubMed ID: 15895714
[TBL] [Abstract][Full Text] [Related]
25. Mucopolysaccharidosis type I subtypes. Presence of immunologically cross-reactive material and in vitro enhancement of the residual alpha-L-iduronidase activities.
Schuchman EH; Desnick RJ
J Clin Invest; 1988 Jan; 81(1):98-105. PubMed ID: 3121676
[TBL] [Abstract][Full Text] [Related]
26. A Humoral Immune Response Alters the Distribution of Enzyme Replacement Therapy in Murine Mucopolysaccharidosis Type I.
Le SQ; Kan SH; Clarke D; Sanghez V; Egeland M; Vondrak KN; Doherty TM; Vera MU; Iacovino M; Cooper JD; Sands MS; Dickson PI
Mol Ther Methods Clin Dev; 2018 Mar; 8():42-51. PubMed ID: 29159202
[TBL] [Abstract][Full Text] [Related]
27. Specific antibody titer alters the effectiveness of intrathecal enzyme replacement therapy in canine mucopolysaccharidosis I.
Dickson PI; Ellinwood NM; Brown JR; Witt RG; Le SQ; Passage MB; Vera MU; Crawford BE
Mol Genet Metab; 2012 May; 106(1):68-72. PubMed ID: 22402327
[TBL] [Abstract][Full Text] [Related]
28. Reversal of lysosomal storage in brain of adult MPS-I mice with intravenous Trojan horse-iduronidase fusion protein.
Boado RJ; Hui EK; Lu JZ; Zhou QH; Pardridge WM
Mol Pharm; 2011 Aug; 8(4):1342-50. PubMed ID: 21667973
[TBL] [Abstract][Full Text] [Related]
29. Immune response hinders therapy for lysosomal storage diseases.
Ponder KP
J Clin Invest; 2008 Aug; 118(8):2686-9. PubMed ID: 18654672
[TBL] [Abstract][Full Text] [Related]
30. Effect of anti-laronidase antibodies on efficacy and safety of laronidase enzyme replacement therapy for MPS I: A comprehensive meta-analysis of pooled data from multiple studies.
Xue Y; Richards SM; Mahmood A; Cox GF
Mol Genet Metab; 2016 Apr; 117(4):419-26. PubMed ID: 26920513
[TBL] [Abstract][Full Text] [Related]
31. Laronidase treatment of mucopolysaccharidosis I.
Wraith EJ; Hopwood JJ; Fuller M; Meikle PJ; Brooks DA
BioDrugs; 2005; 19(1):1-7. PubMed ID: 15691212
[TBL] [Abstract][Full Text] [Related]
32. Intranasal Adeno-Associated Virus Mediated Gene Delivery and Expression of Human Iduronidase in the Central Nervous System: A Noninvasive and Effective Approach for Prevention of Neurologic Disease in Mucopolysaccharidosis Type I.
Belur LR; Temme A; Podetz-Pedersen KM; Riedl M; Vulchanova L; Robinson N; Hanson LR; Kozarsky KF; Orchard PJ; Frey WH; Low WC; McIvor RS
Hum Gene Ther; 2017 Jul; 28(7):576-587. PubMed ID: 28462595
[TBL] [Abstract][Full Text] [Related]
33. Production of α-L-iduronidase in maize for the potential treatment of a human lysosomal storage disease.
He X; Haselhorst T; von Itzstein M; Kolarich D; Packer NH; Gloster TM; Vocadlo DJ; Clarke LA; Qian Y; Kermode AR
Nat Commun; 2012; 3():1062. PubMed ID: 22990858
[TBL] [Abstract][Full Text] [Related]
34. Mucopolysaccharidosis type I: characterization of novel mutations affecting alpha-L-iduronidase activity.
Lee-Chen GJ; Lin SP; Tang YF; Chin YW
Clin Genet; 1999 Jul; 56(1):66-70. PubMed ID: 10466419
[TBL] [Abstract][Full Text] [Related]
35. Enzyme replacement in a canine model of Hurler syndrome.
Shull RM; Kakkis ED; McEntee MF; Kania SA; Jonas AJ; Neufeld EF
Proc Natl Acad Sci U S A; 1994 Dec; 91(26):12937-41. PubMed ID: 7809150
[TBL] [Abstract][Full Text] [Related]
36. Role of rehabilitation in Hurler's syndrome.
Mishra SR; Shastri M; Ramesh J
J Back Musculoskelet Rehabil; 2017; 30(3):635-639. PubMed ID: 27911282
[TBL] [Abstract][Full Text] [Related]
37. The alpha-L-iduronidase mutations R89Q and R89W result in an attenuated mucopolysaccharidosis type I clinical presentation.
Hein LK; Hopwood JJ; Clements PR; Brooks DA
Biochim Biophys Acta; 2003 Oct; 1639(2):95-103. PubMed ID: 14559116
[TBL] [Abstract][Full Text] [Related]
38. Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I.
Kakkis E; McEntee M; Vogler C; Le S; Levy B; Belichenko P; Mobley W; Dickson P; Hanson S; Passage M
Mol Genet Metab; 2004; 83(1-2):163-74. PubMed ID: 15464431
[TBL] [Abstract][Full Text] [Related]
39. Transcranial pulsed ultrasound facilitates brain uptake of laronidase in enzyme replacement therapy for Mucopolysaccharidosis type I disease.
Hsu YH; Liu RS; Lin WL; Yuh YS; Lin SP; Wong TT
Orphanet J Rare Dis; 2017 Jun; 12(1):109. PubMed ID: 28595620
[TBL] [Abstract][Full Text] [Related]
40. Outcome after three years of laronidase enzyme replacement therapy in a patient with Hurler syndrome.
Thomas JA; Jacobs S; Kierstein J; Van Hove J
J Inherit Metab Dis; 2006 Dec; 29(6):762. PubMed ID: 17089217
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
